Ayelet Dilion-Mashiah
CEO
Claimed by owner NewStem
Former names:
Diagnostic Kit for Predicting Chemotherapy Resistance
NewStem
www.prnewswire.com
•
Sep 15, 2022
Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
www.prnewswire.com
•
Apr 11, 2022
NewStem Files FDA Pre-Submission and EMA IVDD for Revolutionary Life-Saving, Treatment-Changing Diagnostic Device
www.globenewswire.com
•
Apr 21, 2020
NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance;Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments
www.jns.org
•
May 22, 2019
New York's Yeshiva University inaugurates Innovation Lab, in partnership with Israel
en.globes.co.il
•
Jul 16, 2018
Israeli chemotherapy co NewStem raises $4m
www.timesofisrael.com
•
Jul 16, 2018
Israeli stem cell startup raises $4 million for chemo effectiveness technology
www.israelscienceinfo.com
•
Nov 16, 2017
NewStem (Hebrew U. Israel) Introduces Novel Technology for Predicting Resistance to Chemotherapies - Israël Science Info
www.israel21c.org
•
May 24, 2017
New technology can predict resistance to chemotherapy
About
NewStem has developed a novel technology for predicting resistance to anticancer treatments. The company is creating a diagnostic tool based on pioneering research in the field of human haploid pluripotent stem cells (HHPSCs), which are used for a variety of applications, ranging from basic research to therapeutics.
Anticancer treatment often results in tumor resistance to the drugs used. Due to the differentiation capacity of pluripotent stem cells, one potential use is to assess the influence of mutated genes on a variety of cells, physiological processes, and drug responses. Human cells contain two copies of each gene (diploid cells), making it difficult to generate cells in which both copies of the relevant genes are mutated.
NewStems findings enable the generation of fully functional stem cells containing only one copy of each gene (haploid cells). A unique and broad library of HHPSCs with different mutations and genetic makeups is enabling NewStem to develop diagnostic tools for personalized medicine.
NewStem is a spin-off of Yissum Research Development Company of the Hebrew University of Jerusalem.
Anticancer treatment often results in tumor resistance to the drugs used. Due to the differentiation capacity of pluripotent stem cells, one potential use is to assess the influence of mutated genes on a variety of cells, physiological processes, and drug responses. Human cells contain two copies of each gene (diploid cells), making it difficult to generate cells in which both copies of the relevant genes are mutated.
NewStems findings enable the generation of fully functional stem cells containing only one copy of each gene (haploid cells). A unique and broad library of HHPSCs with different mutations and genetic makeups is enabling NewStem to develop diagnostic tools for personalized medicine.
NewStem is a spin-off of Yissum Research Development Company of the Hebrew University of Jerusalem.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
Israel
News
(8)
www.prnewswire.com
•
Sep 15, 2022
Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
www.prnewswire.com
•
Apr 11, 2022
NewStem Files FDA Pre-Submission and EMA IVDD for Revolutionary Life-Saving, Treatment-Changing Diagnostic Device
www.globenewswire.com
•
Apr 21, 2020
NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance;Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments
www.jns.org
•
May 22, 2019
New York's Yeshiva University inaugurates Innovation Lab, in partnership with Israel
en.globes.co.il
•
Jul 16, 2018
Israeli chemotherapy co NewStem raises $4m
www.timesofisrael.com
•
Jul 16, 2018
Israeli stem cell startup raises $4 million for chemo effectiveness technology
www.israelscienceinfo.com
•
Nov 16, 2017
NewStem (Hebrew U. Israel) Introduces Novel Technology for Predicting Resistance to Chemotherapies - Israël Science Info
www.israel21c.org
•
May 24, 2017
New technology can predict resistance to chemotherapy
The Team
(3)
OK
Oded Kopper
VP R&D
NB
Nissim Benvenisty
Research Director
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
$4M
Jul 2018
1 Investors
$4M
Seed
$1M
Dec 2019
1 Investors
$1M
Undisclosed Round
Undisclosed
Sep 2021
1 Investors
Undisclosed
Others
Academic Techonology
Sep 2016
undefined
Haploid pluripotent stem cell-based treatment
Affiliation
Mar 2022
Hub Name
Illumina Accelerator Cambridge
Batch
3
Media gallery
(2)
NewStem Ltd. Presents Haploid Human Embryonic Stem Cells
Newstem | How Stem Cell Diagnostics Help Cure Cancer | Whiteboard Animation
Locations
Israel
Givat Ram, Jerusalem, Israel
Locations
Israel
Givat Ram, Jerusalem, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,